The strengths of blockchain technologies could help address the weaknesses of health care systems to store and secure medical records.
L’expertise universitaire, l’exigence journalistique
Articles sur Clinical trials
Affichage de 61 à 80 de 149 articles
An autoimmune disease called vitiligo causes white spots to appear on the body, in some cases completely erasing an individual's pigmentation. But a new therapy is on the horizon.
Clinical trials involving probiotics are failing to report on the safety and harms of these treatments.
As medicines, not all cannabis products are created equal.
Stating a majority of people won't benefit from a vaccine ignores the purpose of immunisation programs.
African countries should be looking to initiate or host more clinical trials to improve the continent's health systems.
You should be aware of the amount of genetic information you might disclose in a research study – and what the benefits and risks will be.
In this clinical trial, the first of its kind, physicians explore whether directly applying a 'good' strain of bacteria to the skin can heal eczema
Study of the "memory centres" of the brain in adults offers hope for detecting Alzheimer's disease earlier -- before the onset of memory loss.
All multiple sclerosis sufferers have stem cells with the potential to heal them, but scientists are only just figuring out how to kick them into action.
Health Canada is proposing to allow some prescription drugs into the country with only 'cursory clinical review.' Here's why we should be worried.
Coordinated international efforts may be key to improving the life expectancy and health of many snakebite victims.
There are several things we can do to speed up the development of new drugs, without putting patients at risk.
How a technology born from finance – the blockchain – can help the pharmaceutical industry to carry out clinical trials that protect patients.
For some patients, drilling a hole in the skull and inserting an electrode into the 'sadness centre' of the brain offers relief from debilitating and otherwise treatment-resistant depression.
We need to ensure cancer research addresses what matters most.
A family physician and public health researcher explains why he isn't getting a prostate cancer test in Movember or at any time in the near future.
Only around 10% of new drugs in development make it onto the market. A drug needs to go through animal trials, and then four phases of human trials to be deemed suitable for use in patients.
A randomised controlled trial is the best way to compare a new treatment with the standard treatment. And randomising trial participants is a core feature of the experiment.
Rare cancers are hard to research given the few patients that have each type of cancer, so how can we improve treatment for these patients?
Les contributeurs les plus fréquents
-
Associate Professor of the Sydney Pharmacy School, University of Sydney
-
Director of the Oxford Empathy Programme, University of Oxford
-
Epidemiologist, Cochrane
-
Professor Emeritus of Health Policy and Management, York University, Emergency Physician at University Health Network, Associate Professor of Family and Community Medicine, University of Toronto
-
Professor of Immunology, RMIT University
-
Professor of Medicine, Monash University
-
Professor of Bioethics & Medicine, Sydney Health Ethics, Haematologist/BMT Physician, Royal North Shore Hospital and Director, Praxis Australia, University of Sydney
-
Senior Research Fellow, Bioethics, University of Sydney
-
Ian Haines est un·e ami·e de La Conversation
Adjunct Clinical Associate Professor, AMREP Department of Medicine, Alfred Hospital, Melbourne & Senior Medical Oncologist and Palliative Care Physician, Melbourne Oncology Group, Cabrini Haematology and Oncology Centre, Wattletree Road, Malvern, Monash University
-
Head, Cancer Research Program, Monash University
-
Senior Lecturer in Medical Ethics and Law, St George's, University of London
-
Researcher, L’Université d’Ottawa/University of Ottawa
-
Professsor of Public Health; Co-Director Consortium for Advanced Research Training in Africa; Panel Member, Private Healthcare Market Inquiry, University of the Witwatersrand
-
Assistant Professor of Law, Saint Louis University
-
Associate professor, UNSW
